Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma  Sergio Bracarda, Alain Ravaud, Marino Chiodi  European Urology Supplements  Volume 8, Issue 10, Pages 815-819 (November 2009) DOI: 10.1016/j.eursup.2009.08.007 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 (a) Lung computed tomography (CT) scan and (b) abdominal CT scan of a patient with metastatic renal cell carcinoma prior to treatment with everolimus; (c) lung CT scan and (d) abdominal CT scan of patient 16 mo after initiation of everolimus treatment. Arrows indicate metastases. European Urology Supplements 2009 8, 815-819DOI: (10.1016/j.eursup.2009.08.007) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 2 (a) Computed tomography scan showing mediastinal lymph node metastases; (b) evidence of significant reduction after 8 mo of treatment with open-label everolimus. European Urology Supplements 2009 8, 815-819DOI: (10.1016/j.eursup.2009.08.007) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 3 Summary of responses to treatment over time in two patients with metastatic renal cell carcinoma. Approximate timelines are given. IFN-α=interferon alfa; VEGF=vascular endothelial growth factor. European Urology Supplements 2009 8, 815-819DOI: (10.1016/j.eursup.2009.08.007) Copyright © 2009 European Association of Urology Terms and Conditions